+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Intranasal Drug & Vaccine Delivery Market by Drug Type, Formulation Type, Device Type, Dosage, Application, End-User - Global Forecast to 2030- Product Image
Intranasal Drug & Vaccine Delivery Market by Drug Type, Formulation Type, Device Type, Dosage, Application, End-User - Global Forecast to 2030- Product Image
Sale

Intranasal Drug & Vaccine Delivery Market by Drug Type, Formulation Type, Device Type, Dosage, Application, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5533387
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Intranasal Drug & Vaccine Delivery Market grew from USD 49.59 billion in 2024 to USD 52.43 billion in 2025. It is expected to continue growing at a CAGR of 5.94%, reaching USD 70.12 billion by 2030.

Setting the Stage for Intranasal Therapeutics Innovation

Intranasal delivery has rapidly evolved from a niche application into a cornerstone of drug and vaccine administration. This summary introduces the transformative potential of delivering therapeutics directly through the nasal mucosa, bypassing the gastrointestinal tract and first-pass metabolism. It highlights how precision targeting, rapid onset of action, and patient-friendly administration are reshaping clinical strategies across diverse therapeutic areas.

This section sets the stage by contextualizing the scientific advances in formulation science and device engineering that have propelled intranasal platforms forward. It illuminates the convergence of biotechnology, material science, and digital health in enabling tailored delivery systems. As regulatory bodies increasingly recognize the safety and efficacy of intranasal routes, the market stands poised for robust expansion.

Readers will gain a clear view of the key factors driving adoption, including patient convenience, reduced systemic side effects, and improved adherence. The introduction underscores why stakeholders-from pharmaceutical developers to healthcare providers-must reexamine traditional distribution channels and embrace intranasal delivery as an integral component of future therapeutic arsenals.

Emerging Paradigm Shifts Redefining Intranasal Delivery

Recent years have witnessed a confluence of scientific breakthroughs and shifting healthcare priorities that are redefining how intranasal therapeutics fit into broader treatment paradigms. Advances in mucoadhesive polymers and nanoparticle carriers have enhanced the precision and consistency of drug deposition along the nasal cavity, elevating efficacy across small molecules and biologics alike.

Moreover, the surge in demand for non-invasive vaccination methods has accelerated investment in nasal spray platforms that can induce mucosal and systemic immunity without the need for cold chain logistics. This shift has spurred a new wave of research into needle-free technologies that promise to widen immunization coverage, especially in resource-constrained settings.

In parallel, digital inhalation monitoring and IoT-enabled devices are converging with intranasal systems to improve adherence tracking and patient engagement. As healthcare systems worldwide prioritize outpatient care and patient self-administration, intranasal delivery is transforming from a complementary option into a strategic necessity for achieving optimized therapeutic outcomes.

Assessing the 2025 US Tariff Impact on Intranasal Market Dynamics

The introduction of new tariffs by the United States in early 2025 has introduced significant cost pressures on raw materials and device components sourced internationally. Manufacturers reliant on polymeric substrates, specialized excipients, and precision device parts have seen their production economics shift markedly.

These obligations have prompted a reevaluation of global supply chains, encouraging regional sourcing and nearshoring to mitigate tariff burdens. Companies are forging strategic partnerships with domestic suppliers and investing in local manufacturing capabilities to maintain cost competitiveness. Simultaneously, these adjustments have fueled innovation in alternative, tariff-exempt materials and streamlined device designs that reduce import dependencies.

Consequently, the tariff landscape is driving a broader reassessment of value chains, with a growing emphasis on vertical integration and end-to-end process optimization. Organizations that proactively adapt their procurement strategies, while advancing cost-effective formulation and device innovations, will be best positioned to navigate the evolving regulatory and economic environment.

Uncovering Market Drivers Through Segmentation Insights

A nuanced understanding of market segmentation reveals the distinct dynamics shaping intranasal delivery. Within drug type, analgesics from non-opioid pain relievers to potent opioid formulations compete alongside antihistamines, anti-inflammatory steroids and an array of vaccine technologies that range from traditional inactivated strains to live attenuated and cutting-edge mRNA constructs. Each category demands tailored formulation strategies to optimize nasal absorption and immune activation.

Formulation type further differentiates product performance. Gels provide sustained mucosal contact, liquids offer rapid onset, and dry powders enhance stability and room-temperature storage. The choice of device drives patient experience and dosing precision, with atomizers achieving fine droplet dispersion, nasal droppers enabling targeted application and metered nasal sprays delivering controlled doses.

Dosage considerations-whether multi-dose formats for ongoing therapies or single-use unit-dose systems for vaccine campaigns-shape packaging design and patient compliance. Meanwhile, therapeutic aspirations span allergy treatment, hormone replacement, neurological interventions, pain management protocols, psychiatric disorder management and broad therapeutic delivery campaigns. Each use case influences the complexity of dosing regimens and regulatory pathways.

End-user settings underscore market adoption patterns. The convenience of homecare enables at-home self-administration, whereas hospitals and clinics demand integration with existing care workflows. Research and academic institutions continue to explore novel molecules and device modalities, driving the next wave of product innovation.

Dissecting Regional Trends in Intranasal Delivery Adoption

Regional distinctions in intranasal delivery adoption reveal strategic growth corridors and unique challenges. In the Americas, well-established pharmaceutical infrastructure and robust reimbursement frameworks have accelerated uptake of both prescription analgesics and vaccine sprays, while digital health integration is rapidly advancing patient adherence tracking.

Across Europe, the Middle East and Africa, regulatory harmonization efforts and expanding vaccination initiatives have created fertile ground for intranasal immunization campaigns. Market entry requires navigating diverse health authorities and tailoring devices for varied cold chain capacities, yet emerging collaborations are streamlining cross-border distribution.

In the Asia-Pacific region, burgeoning middle-class populations and expanding access to primary care clinics have fueled demand for cost-effective, needle-free therapies. This environment has incentivized local manufacturing to serve high-volume vaccine programs, while rising interest in mental health and neurological treatments is driving innovation in intranasal formulations targeting central nervous system delivery.

These regional insights underscore the importance of adaptive strategies that align with local healthcare priorities, reimbursement models and supply chain realities to capture maximum value across global markets.

Profiling Leading Players Shaping the Intranasal Delivery Arena

Leading innovators have seized the opportunity to redefine patient care through intranasal platforms. Biotech pioneers have advanced mRNA-based nasal vaccines, demonstrating mucosal immunogenicity profiles that rival injection-based approaches. Pharmaceutical incumbents have expanded beyond antihistamines and analgesics into intranasal steroid therapies, leveraging proprietary mucoadhesive formulations to achieve extended release.

Device manufacturers have introduced next-generation atomization technologies that calibrate droplet size and velocity to maximize mucosal uptake, while others have streamlined device manufacturing costs through modular, scalable designs. Collaborative alliances between drug formulators and device specialists are accelerating go-to-market timelines, setting new benchmarks for regulatory approvals.

Meanwhile, contract development and manufacturing organizations are investing in specialized cleanroom facilities and nasal-specific fill-finish lines, enabling clients to transition swiftly from clinical to commercial scale. Collectively, these companies are orchestrating an ecosystem that spans molecule design, formulation engineering and device integration-paving the way for the broader adoption of intranasal therapeutics.

Strategic Imperatives for Industry Leadership in Intranasal Delivery

Companies aiming to lead in the intranasal space must forge a dual focus on innovation and operational strength. Investing in advanced mucoadhesive polymers and nanoparticle carriers will drive next-generation formulations, while partnerships with digital health providers can enhance patient monitoring and adherence through connected devices. Strengthening local supply chains and establishing strategic alliances with regional manufacturers will mitigate tariff and logistics risks, optimizing cost structures.

Portfolio diversification across drug categories-ranging from pain management and psychiatric applications to hormone replacement and vaccines-will spread risk and capture emerging therapeutic opportunities. Adopting modular device platforms that accommodate multiple formulation types allows for rapid product line extensions and regulatory filings across markets. In parallel, embedding sustainability practices in sourcing and packaging can resonate with both regulators and payers, fostering patient trust.

By aligning R&D roadmaps with evolving clinical needs in neurological and immunological applications, industry leaders can secure first-mover advantage. Cultivating cross-functional teams that integrate regulatory affairs, clinical development and supply chain logistics will ensure agile responses to shifting market demands and geopolitical headwinds.

Robust Research Methodology Underpinning Market Insights

This analysis draws upon a rigorous mixed-methodology approach. Primary interviews with key opinion leaders and senior executives provided qualitative insights into clinical challenges and commercial strategies. Secondary research encompassed peer-reviewed journals, patent filings and regulatory agency publications to validate technological advances and policy developments.

A detailed review of device registries and formulation patent landscapes enabled mapping of competitive positioning, while examination of trade and tariff databases informed the assessment of supply chain vulnerabilities. Regional market dynamics were cross-referenced with healthcare expenditure reports and immunization program data to identify growth hotspots.

Quantitative analysis leveraged transaction databases and investment trends to delineate M&A activity, strategic partnerships and funding patterns. The integration of these research strands offers a holistic view of the intranasal delivery ecosystem, ensuring that strategic recommendations rest on robust empirical foundations.

Synthesis of Intranasal Delivery Market Learnings and Outlook

The intranasal delivery market stands at a pivotal juncture, propelled by advances in formulation and device technology, evolving healthcare delivery models and targeted immunization efforts. The interplay of segmentation dynamics-from drug categories and formulation formats to device modalities and end-user environments-reveals a complex matrix of opportunities and challenges.

Tariff shifts in the United States underscore the need for agile supply chain strategies, while regional nuances demand tailored regulatory and commercialization roadmaps. Leading companies have demonstrated that integrated innovation-spanning molecule, formulation and device-yields significant competitive advantage. Strategic imperatives now call for diversification, sustainability integration and digital health synergies to capture the next wave of growth.

As stakeholders chart their course, the insights and recommendations presented here offer a clear framework for decision-making. By embedding these learnings into R&D and commercial strategies, organizations can harness the full potential of intranasal delivery to drive patient outcomes and secure market leadership.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Type
    • Analgesics
      • Non-opioids
      • Opioids
    • Antihistamines
    • Steroids
    • Vaccines
      • Inactivated Vaccines
      • Live Attenuated Vaccines
      • mRNA-based Vaccine
  • Formulation Type
    • Gel Formulations
    • Liquid Formulations
    • Powder Formulations
  • Device Type
    • Atomizer
    • Nasal Dropper
    • Nasal Spray
  • Dosage
    • Multi-dose
    • Unit-dose
  • Application
    • Allergy Treatment
    • Hormone Replacement
    • Neurological Conditions
    • Pain Management
    • Psychiatric Disorders
    • Therapeutic Drug Delivery
  • End-User
    • Homecare
    • Hospitals & Clinics
    • Research & Academic Institution
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Altimmune, Inc.
  • AptarGroup, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Becton, Dickinson, and Company
  • Bharat Biotech Ltd.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • DCA Design International Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Hovione Limited
  • Impel Pharmaceuticals LLC.
  • Indivior PLC
  • Intersect ENT by Medtronic plc
  • Intertek Group PLC
  • Johnson & Johnson Services, Inc.
  • Kindeva Drug Delivery L.P.
  • Merck & Co., Inc.
  • Neurelis, Inc.
  • Novartis AG
  • OptiNose, Inc.
  • Pfizer Inc.
  • Recipharm AB.
  • Sanofi S.A.
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising disease prevalence and syringe infection concerns propel growth in intranasal delivery systems
5.1.1.2. Increasing popularity of self-administration of medications and non-invasive drug delivery routes
5.1.1.3. Growing research and development activities focusing on innovations in intranasal vaccines
5.1.2. Restraints
5.1.2.1. Availability of alternative drug delivery methods and potential risk of product recalls
5.1.3. Opportunities
5.1.3.1. Advancements related to intranasal drug delivery systems
5.1.3.2. Substantial investments for R&D intranasal drug and vaccines delivery innovations
5.1.4. Challenges
5.1.4.1. Potential adverse reactions and side effects associated with intranasal drug administration
5.2. Market Segmentation Analysis
5.2.1. Drug Type: Growing usage of non-opioid analgesics for chronic pain and long-term use owing to the lower risk of addiction and side effects
5.2.2. Formulation Type: Innovative solutions and emerging applications in intranasal drug & vaccine delivery
5.2.3. Device Type: Rising demand for atomizers owing to precision and efficacy in emergency treatments
5.2.4. Dosage: Growing preference for multi-dose formats in large-scale immunization programs and chronic treatment protocols owing to cost-effectiveness and material efficiency
5.2.5. Application: Rising preference for intranasal drug & vaccine delivery in allergy treatment to administer corticosteroids and antihistamines
5.2.6. End-User: Expanding utilization of intranasal drug & vaccine delivery in homecare setups owing to better convenience and privacy
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Intranasal Drug & Vaccine Delivery Market, by Drug Type
6.1. Introduction
6.2. Analgesics
6.2.1. Non-opioids
6.2.2. Opioids
6.3. Antihistamines
6.4. Steroids
6.5. Vaccines
6.5.1. Inactivated Vaccines
6.5.2. Live Attenuated Vaccines
6.5.3. mRNA-based Vaccine
7. Intranasal Drug & Vaccine Delivery Market, by Formulation Type
7.1. Introduction
7.2. Gel Formulations
7.3. Liquid Formulations
7.4. Powder Formulations
8. Intranasal Drug & Vaccine Delivery Market, by Device Type
8.1. Introduction
8.2. Atomizer
8.3. Nasal Dropper
8.4. Nasal Spray
9. Intranasal Drug & Vaccine Delivery Market, by Dosage
9.1. Introduction
9.2. Multi-dose
9.3. Unit-dose
10. Intranasal Drug & Vaccine Delivery Market, by Application
10.1. Introduction
10.2. Allergy Treatment
10.3. Hormone Replacement
10.4. Neurological Conditions
10.5. Pain Management
10.6. Psychiatric Disorders
10.7. Therapeutic Drug Delivery
11. Intranasal Drug & Vaccine Delivery Market, by End-User
11.1. Introduction
11.2. Homecare
11.3. Hospitals & Clinics
11.4. Research & Academic Institution
12. Americas Intranasal Drug & Vaccine Delivery Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Intranasal Drug & Vaccine Delivery Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Intranasal Drug & Vaccine Delivery Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.3.1. Orexo and Abera collaborate to advance intranasal powder vaccine development
15.3.2. AuraVax Therapeutics secures a research contract from BARDA to investigate NanoSTING platform
15.3.3. Aptar Pharma's strategic acquisition of SipNose enhances innovation in intranasal drug delivery systems
15.3.4. FDA approval for at-home FluMist nasal spray offers needle-free solution to boost flu vaccination rates
15.3.5. Rokote Laboratories partners with 3PBIOVIAN to advance intranasal COVID-19 vaccine manufacturing for clinical trials
15.3.6. CastleVax secures USD 34 million funding to propel innovative intranasal COVID-19 vaccine into advanced trials
15.3.7. BARDA invests USD 500 million in next-generation intranasal and oral COVID-19 vaccines
15.3.8. Merck Animal Health transforms intranasal vaccination with innovative CleanVax nozzles and shields for enhanced hygiene and comfort
15.3.9. Strategic collaboration to innovate nasal drug delivery with soft mist technology
15.3.10. Kindeva expands intranasal drug-delivery capabilities with Summit Biosciences acquisition
15.3.11. Oragenics acquisitions advance intranasal drug delivery for neurological treatments and market expansion
15.4. Strategy Analysis & Recommendation
15.4.1. AstraZeneca PLC
15.4.2. Pfizer Inc.
15.4.3. Indivior PLC
15.4.4. AptarGroup, Inc.
List of Figures
FIGURE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET MULTI-CURRENCY
FIGURE 2. INTRANASAL DRUG & VACCINE DELIVERY MARKET MULTI-LANGUAGE
FIGURE 3. INTRANASAL DRUG & VACCINE DELIVERY MARKET RESEARCH PROCESS
FIGURE 4. INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
FIGURE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. INTRANASAL DRUG & VACCINE DELIVERY MARKET DYNAMICS
TABLE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 68. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 69. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 70. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 71. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 72. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 110. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 111. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 112. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 113. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 114. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 117. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 118. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 119. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 120. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 121. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 122. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 134. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 135. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 136. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 137. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 138. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 145. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 146. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 153. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 154. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 161. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 162. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 169. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 170. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 177. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 178. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 182. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 183. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 184. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 185. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 186. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 193. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 194. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 205. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 206. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 207. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 208. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 209. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 210. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 211. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 214. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 215. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 216. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 217. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 218. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 219. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 222. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 224. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 225. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 226. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 227. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 230. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 231. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 232. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 233. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 234. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 235. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 238. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 239. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 240. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 241. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 242. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 243. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 250. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 251. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 254. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 255. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 256. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 257. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 258. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 259. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 278. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 279. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 280. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 281. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 282. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 283. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 286. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 287. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 288. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 289. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 290. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 291. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 293. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 294. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 295. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 296. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 297. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 298. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 299. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 300. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA INTRANASAL D

Companies Mentioned

The companies profiled in this Intranasal Drug & Vaccine Delivery market report include:
  • Altimmune, Inc.
  • AptarGroup, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Becton, Dickinson, and Company
  • Bharat Biotech Ltd.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • DCA Design International Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Hovione Limited
  • Impel Pharmaceuticals LLC.
  • Indivior PLC
  • Intersect ENT by Medtronic plc
  • Intertek Group PLC
  • Johnson & Johnson Services, Inc.
  • Kindeva Drug Delivery L.P.
  • Merck & Co., Inc.
  • Neurelis, Inc.
  • Novartis AG
  • OptiNose, Inc.
  • Pfizer Inc.
  • Recipharm AB.
  • Sanofi S.A.
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 52.43 Billion
Forecasted Market Value ( USD ) by 2030 $ 70.12 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Intranasal Drug and Vaccine Delivery Market Size, Share & Trends Analysis Report by Product, Dosage, Application, Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Intranasal Drug and Vaccine Delivery Market Size, Share & Trends Analysis Report by Product, Dosage, Application, Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Vaccine Delivery Devices - Global Strategic Business Report - Product Image

Vaccine Delivery Devices - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Global Vaccine Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Vaccine Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 120 Pages
  • Global
From
Vaccine Delivery Devices Market by Device Type, Administration Route, End User, Product Form - Global Forecast to 2030 - Product Image

Vaccine Delivery Devices Market by Device Type, Administration Route, End User, Product Form - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Vaccine Delivery Devices Market Size, Share & Trends Analysis Report By Device (Syringes, Jet Injectors), By Route Of Administration (Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Vaccine Delivery Devices Market Size, Share & Trends Analysis Report By Device (Syringes, Jet Injectors), By Route Of Administration (Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 170 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.